🏛️ Verified NIH Record • Updated 2026-05-01
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (NCT06014762)
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Poseida Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
Who can join: Review the eligibility criteria below.
Location: Loma Linda University Cancer Center — Loma Linda, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Loma Linda University Cancer Center — Loma Linda, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Advent Health Orlando — Orlando, Florida
- Indiana University — Indianapolis, Indiana
- Our Lady of the Lake Hospital — Baton Rouge, Louisiana
- Ochsner Clinic Foundation — New Orleans, Louisiana
- Wayne State - Karmanos Cancer Institute — Detroit, Michigan
- NYU Grossman School of Medicine — New York, New York
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- University of Cincinnati — Cincinnati, Ohio
- University of Oklahoma, Health Sciences Center — Oklahoma City, Oklahoma
- Oregon Health & Science University — Portland, Oregon
- Pennsylvania State University — Hershey, Pennsylvania
- Prisma Health - Upstate Cancer Institute — Greenville, South Carolina
- Vanderbilt University Medical Center — Nashville, Tennessee
- Baylor Scott & White Research Institute — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy — Rochester, Minnesota
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — Duarte, California
Explore by condition: All Diffuse Large B-Cell Lymphoma, Not Otherwise Specified clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.